Literature DB >> 9032211

Prostaglandin H synthase 1 and 2 immunoreactivities in the bronchial mucosa of asthmatics.

P Demoly1, D Jaffuel, N Lequeux, B Weksler, C Créminon, F B Michel, P Godard, J Bousquet.   

Abstract

Prostaglandin H synthases or cyclooxygenases 1 (PGHS-1) and 2 (PGHS-2) catalyze the conversion of arachidonic acid to prostaglandin endoperoxides, leading to the formation of prostaglandin and thromboxane mediators of inflammation. The expression of these enzymes in the respiratory epithelium has not been determined, although they may be relevant to the pathophysiology of inflammatory disorders such as asthma and chronic bronchitis (CB). We studied PGHS-1 and PGHS-2 immunoreactivity in bronchial biopsies obtained from 22 patients with chronic stable asthma, seven patients with CB, and 12 normal subjects. Both types of PGHS were mainly expressed in the epithelium (basal and ciliated cells), and PGHS-1 and PGHS-2 were found in 21 of 41 and 34 of 41 biopsies, respectively. We did not find any differences in PGHS expression between the patient populations. There were no correlations between any of the clinical parameters studied or the pathologic patterns and the presence and characteristics of the PGHS immunoreactivities. Thus, both PGHS enzymes are expressed in normal human respiratory epithelium and are not quantitatively upregulated in the main bronchi in stable asthma and CB.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032211     DOI: 10.1164/ajrccm.155.2.9032211

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  9 in total

1.  Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment.

Authors:  A E Redington; Q H Meng; D R Springall; T J Evans; C Créminon; J Maclouf; S T Holgate; P H Howarth; J M Polak
Journal:  Thorax       Date:  2001-05       Impact factor: 9.139

2.  Allergic lung responses are increased in prostaglandin H synthase-deficient mice.

Authors:  S H Gavett; S L Madison; P C Chulada; P E Scarborough; W Qu; J E Boyle; H F Tiano; C A Lee; R Langenbach; V L Roggli; D C Zeldin
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

Review 3.  Crossreacting drugs and chemicals.

Authors:  Katharine M Woessner
Journal:  Clin Rev Allergy Immunol       Date:  2003-04       Impact factor: 8.667

Review 4.  Pathogenesis of aspirin-exacerbated respiratory disease.

Authors:  Donald D Stevenson; Bruce L Zuraw
Journal:  Clin Rev Allergy Immunol       Date:  2003-04       Impact factor: 8.667

Review 5.  The role of prostaglandins in allergic lung inflammation and asthma.

Authors:  Dru Claar; Tina V Hartert; Ray Stokes Peebles
Journal:  Expert Rev Respir Med       Date:  2014-12-26       Impact factor: 3.772

6.  Pulmonary cyclooxygenase-1 (COX-1) and COX-2 cellular expression and distribution after respiratory syncytial virus and parainfluenza virus infection.

Authors:  Zaher A Radi; David K Meyerholz; Mark R Ackermann
Journal:  Viral Immunol       Date:  2010-02       Impact factor: 2.257

7.  Lipidomic characterization and localization of phospholipids in the human lung.

Authors:  Karin A Zemski Berry; Robert C Murphy; Beata Kosmider; Robert J Mason
Journal:  J Lipid Res       Date:  2017-03-09       Impact factor: 5.922

Review 8.  Prostaglandins in asthma and allergic diseases.

Authors:  R Stokes Peebles
Journal:  Pharmacol Ther       Date:  2018-08-03       Impact factor: 12.310

9.  COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease.

Authors:  Leslie J Crofford
Journal:  Arthritis Res Ther       Date:  2002-12-09       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.